CN101416957A - 白藜芦醇或柚皮素预防和治疗糖尿病肾病的应用 - Google Patents
白藜芦醇或柚皮素预防和治疗糖尿病肾病的应用 Download PDFInfo
- Publication number
- CN101416957A CN101416957A CNA2008102391451A CN200810239145A CN101416957A CN 101416957 A CN101416957 A CN 101416957A CN A2008102391451 A CNA2008102391451 A CN A2008102391451A CN 200810239145 A CN200810239145 A CN 200810239145A CN 101416957 A CN101416957 A CN 101416957A
- Authority
- CN
- China
- Prior art keywords
- naringenin
- resveratrol
- application
- diabetes
- diabetic nephropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 title claims abstract description 49
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 235000007625 naringenin Nutrition 0.000 title claims abstract description 49
- 229940117954 naringenin Drugs 0.000 title claims abstract description 49
- 235000021283 resveratrol Nutrition 0.000 title claims abstract description 45
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 title claims abstract description 41
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 title claims abstract description 41
- 229940016667 resveratrol Drugs 0.000 title claims abstract description 41
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims description 22
- 208000033679 diabetic kidney disease Diseases 0.000 title claims description 22
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 5
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims abstract description 4
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims abstract description 4
- 229940099456 transforming growth factor beta 1 Drugs 0.000 claims abstract description 4
- 208000017169 kidney disease Diseases 0.000 claims abstract 3
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 16
- 239000008103 glucose Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 14
- 210000003734 kidney Anatomy 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 229930003935 flavonoid Natural products 0.000 claims description 8
- 150000002215 flavonoids Chemical class 0.000 claims description 8
- 235000017173 flavonoids Nutrition 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 7
- 230000000630 rising effect Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 3
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims description 3
- 206010020710 Hyperphagia Diseases 0.000 claims description 3
- 229940045109 genistein Drugs 0.000 claims description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 3
- 235000006539 genistein Nutrition 0.000 claims description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 3
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims description 3
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims description 3
- 235000010209 hesperetin Nutrition 0.000 claims description 3
- 229960001587 hesperetin Drugs 0.000 claims description 3
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 3
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 3
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 3
- 235000009498 luteolin Nutrition 0.000 claims description 3
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims description 3
- 229930019673 naringin Natural products 0.000 claims description 3
- 229940052490 naringin Drugs 0.000 claims description 3
- 206010036067 polydipsia Diseases 0.000 claims description 3
- 208000022530 polyphagia Diseases 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 238000001647 drug administration Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000452 restraining effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 36
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 30
- 230000001939 inductive effect Effects 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 16
- 229930003944 flavone Natural products 0.000 description 16
- -1 flavone compounds Chemical class 0.000 description 16
- 235000011949 flavones Nutrition 0.000 description 16
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 16
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 15
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 15
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 15
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 14
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 14
- 229960001052 streptozocin Drugs 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 229940026534 resveratrol 50 mg Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000008721 basement membrane thickening Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 210000002601 glomerular mesangium Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 229940048771 resveratrol 100 mg Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102391451A CN101416957B (zh) | 2008-12-10 | 2008-12-10 | 白藜芦醇或柚皮素预防和治疗糖尿病肾病的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008102391451A CN101416957B (zh) | 2008-12-10 | 2008-12-10 | 白藜芦醇或柚皮素预防和治疗糖尿病肾病的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101416957A true CN101416957A (zh) | 2009-04-29 |
CN101416957B CN101416957B (zh) | 2011-06-01 |
Family
ID=40628083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008102391451A Active CN101416957B (zh) | 2008-12-10 | 2008-12-10 | 白藜芦醇或柚皮素预防和治疗糖尿病肾病的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101416957B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780062A (zh) * | 2010-03-22 | 2010-07-21 | 张爱华 | 白藜芦醇在治疗肾脏病中的应用 |
CN102000054A (zh) * | 2010-10-26 | 2011-04-06 | 天津医科大学 | 一种黄酮类似物、制备及其作为抗糖尿病药物的用途 |
CN103355665A (zh) * | 2013-04-11 | 2013-10-23 | 江南大学 | 一种用于降血糖和辅助治疗糖尿病的组合物 |
CN104367568A (zh) * | 2014-11-18 | 2015-02-25 | 南通大学附属医院 | 白黎芦醇在制备治疗慢性衰竭的药物中的应用 |
CN113101295A (zh) * | 2020-03-20 | 2021-07-13 | 上海疆云医疗健康科技有限公司 | 二苯乙烯类似物在治疗糖尿病肾脏疾病中的用途 |
-
2008
- 2008-12-10 CN CN2008102391451A patent/CN101416957B/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101780062A (zh) * | 2010-03-22 | 2010-07-21 | 张爱华 | 白藜芦醇在治疗肾脏病中的应用 |
CN102000054A (zh) * | 2010-10-26 | 2011-04-06 | 天津医科大学 | 一种黄酮类似物、制备及其作为抗糖尿病药物的用途 |
CN102000054B (zh) * | 2010-10-26 | 2014-11-05 | 天津医科大学 | 一种黄酮类似物、制备及其作为抗糖尿病药物的用途 |
CN103355665A (zh) * | 2013-04-11 | 2013-10-23 | 江南大学 | 一种用于降血糖和辅助治疗糖尿病的组合物 |
CN103355665B (zh) * | 2013-04-11 | 2018-08-24 | 江南大学 | 一种用于辅助降血糖的组合物 |
CN104367568A (zh) * | 2014-11-18 | 2015-02-25 | 南通大学附属医院 | 白黎芦醇在制备治疗慢性衰竭的药物中的应用 |
CN113101295A (zh) * | 2020-03-20 | 2021-07-13 | 上海疆云医疗健康科技有限公司 | 二苯乙烯类似物在治疗糖尿病肾脏疾病中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN101416957B (zh) | 2011-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101416957B (zh) | 白藜芦醇或柚皮素预防和治疗糖尿病肾病的应用 | |
CN112716989A (zh) | 一种芹菜籽提取物及其制备方法与应用 | |
CN101810602B (zh) | 化合物3,5,2′,4′-四羟基查尔酮作为制备防治高尿酸血症和痛风药物的应用 | |
CN102702582A (zh) | 玉米须多糖及其制备方法和用途 | |
CN111568948A (zh) | 桑提取物在制备改善胰岛功能药物中的应用 | |
CN105125566B (zh) | 甘露葡萄糖醛酸寡糖及衍生物在制备治疗和/或预防肾病药物或保健品中的应用 | |
CN101375850B (zh) | 去甲异波尔定在制备治疗自身免疫性疾病药物中的应用 | |
CN104208080B (zh) | 调节血糖的药剂 | |
CN104940187A (zh) | 灯盏花乙素苷元的新用途 | |
CN101444599B (zh) | 玉米须提取物及其制备方法和在制备治疗痛风药物中的应用 | |
CN103405494B (zh) | 一种龙须藤正丁醇提取物及其制备方法和用途 | |
CN102293866A (zh) | 一种辅助降血糖的金花茶叶胶囊剂及其制备方法 | |
CN1470513A (zh) | 一种具有抗癌活性的总生物碱及其制剂 | |
KR20180101460A (ko) | 근육의 보호에서 시스탄케 투불로사 추출물 및 이소악테오사이드의 용도 | |
CN100404534C (zh) | 小檗碱衍生物在制备治疗2型糖尿病、调节血糖和血脂的药物中的应用 | |
CN101254200B (zh) | 青钱柳苷类化合物在制备治疗糖尿病药物中的用途 | |
CN110731962B (zh) | 小檗碱、黄连碱或其活性代谢产物、及其盐在预防和/或治疗尿酸性肾病药物中的应用 | |
CN106943408B (zh) | 四甲基尿酸预防和治疗糖尿病的应用 | |
CN110314160A (zh) | 小檗胺在制备预防和治疗糖尿病肾病药物中的应用 | |
CN104547499A (zh) | 一种治疗糖尿病肾病合并动脉粥样硬化的中药组合物 | |
CN100548308C (zh) | 用于自身免疫性疾病和器官移植排异的药物组合物 | |
CN101502536B (zh) | 香柏总黄酮及其制备方法与医药用途 | |
CN109966283A (zh) | 脱脂肉桂多酚提取物在制备防治糖尿病肾病产品中的应用 | |
CN115887513B (zh) | 无瓣海桑嫩枝叶提取物在制备高尿酸血症药物中的应用 | |
CN109820862A (zh) | D-甘露糖在制备抵抗多巴胺减少和/或提升多巴胺水平产品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING WEIHONG HECHUANG MEDICINE TECHNOLOGY CO., Free format text: FORMER OWNER: SHANXI YABAO PHARMACEUTICAL GROUP CORP. Effective date: 20120315 Free format text: FORMER OWNER: BEIJING WEIHONG HECHUANG MEDICINE TECHNOLOGY CO., LTD. Effective date: 20120315 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 044602 YUNCHENG, SHAANXI PROVINCE TO: 100101 CHAOYANG, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120315 Address after: 100101, room 35, South Beach, building 501, Beijing, Chaoyang District Patentee after: BEIJING WEIHONG HECHUANG MEDICINE TECHNOLOGY Co.,Ltd. Address before: 044602 Shanxi city of Yuncheng province Fenglingdu Economic Development Zone No. 1 Industrial Avenue Co-patentee before: BEIJING WEIHONG HECHUANG MEDICINE TECHNOLOGY Co.,Ltd. Patentee before: Shanxi Yabao Pharmaceutical Group Corp. |
|
ASS | Succession or assignment of patent right |
Owner name: ZHAOMING ZEKANG (BEIJING) BIOMEDICAL SCIENCE AND T Free format text: FORMER OWNER: BEIJING WEIHONG HECHUANG MEDICINE TECHNOLOGY CO., LTD. Effective date: 20150112 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150112 Address after: 100101, room 318, building B, Beijing Pioneer Building, No. 11 Xiang Bei Bei, Beijing, Chaoyang District Patentee after: Zhao Ming Zekang (Beijing) biological medicine science and Technology Co.,Ltd. Address before: 100101, room 35, South Beach, building 501, Beijing, Chaoyang District Patentee before: BEIJING WEIHONG HECHUANG MEDICINE TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20240515 Address after: No. 3009-36, 3rd Floor, Building B, Building 1, No. 2 Yongcheng North Road, Haidian District, Beijing, 100094 Patentee after: Beijing Liangyuan Technology Development Center (Limited Partnership) Country or region after: China Address before: 100101 room 318, block B, Beijing venture building, 11 xiangbeili, Chaoyang District, Beijing Patentee before: Zhao Ming Zekang (Beijing) biological medicine science and Technology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |